LY3084077

LY3084077 is a synthetic peptide pharmaceutical compound developed by Eli Lilly. It acts as a selective beta-3 adrenergic receptor agonist, targeting the beta-3 adrenergic receptor to produce its pharmacological effects. The drug has also been described as an FGF21 analogue, indicating it may mimic or modulate fibroblast growth factor 21 activity. Its primary development has focused on metabolic and related indications, though specific disease targets have not been disclosed in public sources. Clinical evaluation has included Phase 1 studies in healthy volunteers to assess safety, tolerability, and pharmacokinetics[1][2][4].